Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Large B-cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• GEN3009

Snippet

Sponsor: Genmab | Conditions: Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-13